A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

R V Iaffaioli; A Tortoriello; G Facchini; M Santangelo; G De Sena; G Gesue; L Bucci; G Scaramellino; E Anastasio; A Finizio

doi:10.1038/bjc.1995.496

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Br J Cancer. 1995 Nov;72(5):1256-8. doi: 10.1038/bjc.1995.496.

Authors

R V Iaffaioli¹, A Tortoriello, G Facchini, M Santangelo, G De Sena, G Gesue, L Bucci, G Scaramellino, E Anastasio, A Finizio, et al.

Affiliation

¹ Istituto di Medicina Interna, Università di Cagliari, Italy.

Abstract

Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Carboplatin / administration & dosage
Carboplatin / adverse effects
Female
Follow-Up Studies
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Leukopenia / chemically induced
Neoplasm Metastasis
Phlebitis / chemically induced
Remission Induction
Salvage Therapy
Treatment Outcome
Vinblastine / administration & dosage
Vinblastine / adverse effects
Vinblastine / analogs & derivatives
Vinorelbine

Substances

Granulocyte Colony-Stimulating Factor
Vinblastine
Carboplatin
Vinorelbine